您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Vancomycin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vancomycin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vancomycin图片
包装:250mg
市场价:450元

产品介绍
Vancomycin is one of the potent antibiotics to perturb the gut microbiota.

Cell lines

B. burgdorferi

Preparation Method

Vancomycin was added at a final concentration of 0.5 -2.0 µg/mL into exponentially growing Borrelia spirochetes and incubated for up to 48 h.

Reaction Conditions

0.5-2.0 µg/mL Vancomycinfor 48 h

Applications

Low to moderate doses of vancomycin ( 2.0 µg/mL for 24 h) produced small alterations in cell shape and that as the dose was increased, cell speed decreased. Vancomycin concentrations >1.0 µg/mL also inhibited cell growth and led to bleb formation on a fraction of the cells.

Animal models

C57BL/6 (Th1) and BALB/c (Th2) of 6-8 weeks

Preparation Method

Both Th1 (C57BL/6)- and Th2 (BALB/c)-biased mice were treated with vancomycin (at 50 mg per kg of body weight) for six consecutive days. 0.5 ml of vancomycin was orally gavaged twice daily at a gap of 12 h. Following the withdrawal of 6 days of treatment with vancomycin, mice were observed for 60 days.

Dosage form

50 mg/kg twice daily at a gap of 12 h,oral

Applications

The gut microbiome profiling, behavior, and immune responses varied significantly between Th1- and Th2-biased mice. By withdrawing the treatment with vancomycin of major gut microbes, important physiological and behavioral changes of both mice strains returned to the normal (untreated control) level.

产品描述

Vancomycin is one of the potent antibiotics to perturb the gut microbiota[1]. Vancomycin treatment caused a significant alteration in the composition and diversity of the commensal gut microbiota of the host[2].Vancomycin specifically blocks peptide cross-linking in the bacterial peptidoglycan by recognizing terminal peptide sequences and blocking their binding site to enzymatic cross-linkers. Vancomycin has previously been shown to be active against B. burgdorferi in vitro[5,6].

Low to moderate doses of vancomycin ( 2.0 µg/mL for 24 h) produced small alterations in cell shape and that as the dose was increased, cell speed decreased. Vancomycin concentrations >1.0 µg/mL also inhibited cell growth and led to bleb formation on a fraction of the cells[3]. The addition of vancomycin at a concentration of 10ug/ml-1 to the wash solution of the cell-saver achieved similar concentrations in the autologous blood concentrate recovered allowing for bacterial removal, with negative blood cultures in all cases[4].

Metagenomic analysis of gut microbiota revealed that the treatment with vancomycin caused a significant decrease in the relative abundance of Firmicutes and Bacteroidetes phyla with a time-dependent increase in Proteobacteria and Verrucomicrobia phyla. Maximum restoration (>70%) of gut microbiota happened by the 15th day of withdrawal of vancomycin. BALB/c mice showed a more efficient restoration of gut microbiota compared to C57BL/6 mice[7]. Mice treated with vancomycin alone had a better clinical outcome in the treatment phase of CDI than mice treated with metronidazole alone[8].

References:
[1]. Carding S, Verbeke K, et,al.Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015 Feb 2;26:26191. doi: 10.3402/mehd.v26.26191. PMID: 25651997; PMCID: PMC4315779.
[2]. Vrieze A, Out C, et,al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014 Apr;60(4):824-31. doi: 10.1016/j.jhep.2013.11.034. Epub 2013 Dec 6. PMID: 24316517
[3]. Harman MW, Hamby AE, et,al. Vancomycin Reduces Cell Wall Stiffness and Slows Swim Speed of the Lyme Disease Bacterium. Biophys J. 2017 Feb 28;112(4):746-754. doi: 10.1016/j.bpj.2016.12.039. PMID: 28256234; PMCID: PMC5340155.
[4]. Perez-Ferrer A, Gredilla-DÍaz E, et,al. Vancomycin added to the wash solution of the cell-saver. Effect on bacterial contamination. Rev Esp Anestesiol Reanim. 2017 Apr;64(4):185-191. English, Spanish. doi: 10.1016/j.redar.2016.10.002. Epub 2017 Jan 13. PMID: 28094033.
[5]. Dever LL, Jorgensen JH, et,al. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother. 1993 May;37(5):1115-21. doi: 10.1128/AAC.37.5.1115. PMID: 8517700; PMCID: PMC187913
[6]. Hunfeld KP, Weigand J, et,al.In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001 Mar;17(3):203-8. doi: 10.1016/s0924-8579(00)00342-3. PMID: 11282265.
[7]. Ray P, Pandey U, et,al.Vancomycin-Induced Changes in Host Immunity and Behavior: Comparative Genomic and Metagenomic Analysis in C57BL/6 and BALB/c Mice. Dig Dis Sci. 2021 Nov;66(11):3776-3791. doi: 10.1007/s10620-020-06729-x. Epub 2021 Jan 1. PMID: 33386517.
[8]. Erikstrup LT, Aarup M, et,al.Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. BMJ Open Gastroenterol. 2015 Nov 2;2(1):e000038. doi: 10.1136/bmjgast-2015-000038. PMID: 26568840; PMCID: PMC4641438.